XASE · Healthcare · Biotechnology
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
IGC’s quarter was weak despite a revenue beat: sales rose to **$265k** from **$191k**, but the biotech remains deeply loss-making with **$2M** in operating loss and EPS missing by $0.01. The updated investor presentation is the only catalyst, and the cash-burning profile still looks highly speculative.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-17 | Q2 2027 | -0.02 | -0.03 | -50.00% | $265,000 | ❌ Miss | +2.89% | +7.36% | — |
| 2026-05-15 | Q1 2027 | — | -0.02 | — | $317,000 | — | +2.13% | +0.70% | -1.96% |
| 2026-03-19 |
| Q3 2026 |
| -0.02 |
| -0.01 |
| +50.00% |
| $213,000 |
| ✅ Beat |
| -0.04% |
| -4.26% |
| +23.49% |
| 2025-11-17 | Q2 2026 | -0.02 | -0.02 | +0.00% | $191,000 | ➖ Inline | — | — | — |
| 2025-08-14 | Q1 2026 | -0.03 | -0.02 | +33.33% | $328,000 | ✅ Beat | +2.75% | -2.33% | +12.75% |
| 2025-02-18 | Q3 2025 | -0.03 | -0.02 | +33.33% | $257,000 | ✅ Beat | -3.70% | -6.36% | +1.61% |
| 2024-06-24 | Q4 2024 | -0.04 | -0.04 | +0.00% | $295,000 | ➖ Inline | -8.10% | -6.43% | -0.30% |
| 2024-02-14 | Q3 2024 | — | -0.09 | — | $204,000 | — | — | — | — |
Showing last 8 quarters.